Description
Products
7 productsPhase 3. Anti-CD40L; systemic lupus erythematosus (SLE).
Under development
Finished product (FDF)
Verified on 2026-10-21
Phase 3. Anti-CD38; antibody-mediated rejection, IgA nephropathy, primary membranous nephropathy (Phase 3); microvascular inflammation (Phase 2).
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Avonex. Neuroscience.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Leqembi (lecanemab-irmb). Partnered product, collaboration with Eisai. Anti-Aβ antibody. In development: presymptomatic Alzheimer's disease (Phase 3).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Phase 3. Anti-BDCA2; systemic lupus erythematosus and cutaneous lupus erythematosus.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Tysabri. Neuroscience.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Plegridy. Neuroscience.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21